Clinical Trial Update: XL092 and Cemiplimab in BRAF WT Thyroid Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update for XL092 in combination with cemiplimab in BRAF wild-type thyroid cancers, including anaplastic thyroid carcinoma, is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Braf Mutation-related Tumors
• Thyroid Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• XL092

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 1 | Status: RECRUITING